AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

Amber Tong

When AstraZeneca wagered $200 million in cash upfront to bring in Ionis’ antisense candidate for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), it was not shy about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Post-Hoc: Pharma CEOs' alternative reality with Trump

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

As­traZeneca says its $200M cash bet on Io­n­is’ AT­TR drug is pay­ing off — with PhI­II da­ta set­ting up FDA fil­ing

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing